Dow Corning Asks Judge To Rule Against Breast Implant Plan Modification
This article was originally published in The Gray Sheet
Payments to the 94% of silicone breast implant claimants who agreed to the Dow Corning Joint Plan of Reorganization should begin soon provided a recent decision by the U.S. Bankruptcy Court to modify the plan is retained.
You may also be interested in...
Proponents of the Dow Corning Joint Plan of Reorganization will present evidence at a June 28 confirmation hearing in the U.S. Bankruptcy Court in Bay City, Michigan in an effort to obtain approval on the plan from the court. On June 1, the Tort Claimants Committee and Dow Corning announced acceptance of the settlement proposal. With more than 300,000 claimant votes submitted on various claim categories, 94% voted in favor of the plan. Court confirmation would allow claimants to select the settlement method for their claim and would resolve the company's Chapter 11 filing
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?